- KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
- KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
- KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
- KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
- KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
- KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
- KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
- KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
More ▼
Key statistics
On Friday, Kalvista Pharmaceuticals Inc (KALV:NMQ) closed at 11.67, 61.86% above the 52 week low of 7.21 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.30 |
---|---|
High | 11.99 |
Low | 11.30 |
Bid | 10.50 |
Offer | 11.99 |
Previous close | 11.25 |
Average volume | 330.50k |
---|---|
Shares outstanding | 42.19m |
Free float | 41.67m |
P/E (TTM) | -- |
Market cap | 492.34m USD |
EPS (TTM) | -3.14 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼